Please try another search
Moderna (NASDAQ:MRNA) announced today a significant reduction in its research and development budget, sending shockwaves through the biotech industry and causing its stock to plummet. The company,...
The 2023 Q3 earnings season kicks off tomorrow with major U.S. banks leading the way Despite the bleak backdrop, S&P 500's Q3 earnings outlook is not as bad as expected This earnings season is set...
Moderna (NASDAQ:MRNA) shares closed lower on Tuesday after the vaccine maker said that its vaccine against seasonal flu did not achieve “early success” in the Phase 3 trial. Following...
Biotech company Moderna (NASDAQ:MRNA) is seeing its shares trade under pressure in recent days after the company reported last week Phase 3 trial results for its flu vaccine candidate, mRNA-1010, in...
PCE inflation data, Fed FOMC minutes, retailer earnings in focus. Walmart stock is a buy amid strong results, upbeat guidance. Moderna shares set to underperform on big profit drop, sluggish...
MRNA is an exceptionally difficult stock to value, given enormous uncertainty surrounding its COVID-19 vaccine and other drugs in its pipeline But there is a case that an enterprise value still over...
EU attempting to revive Iran nuclear deal with market staying pessimistic Crude prices could rebound from oversold conditions but stay off 2022 highs Both Iran, US likely looking for 'win' or...
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review